Olfactory dysfunction in neurodegenerative conditions such as Parkinson's syndrome and Alzheimer's disease can hallmark disease onset. We hypothesized that patients with diabetes mellitus, a condition featuring peripheral and central neurodegeneration, would have decreased olfaction abilities. We examined participants with diabetic peripheral neuropathy, participants with diabetes without diabetic peripheral neuropathy, and control participants in blinded fashion using standardized Sniffin' Sticks. Diabetic peripheral neuropathy severity was quantified using the Utah Early Neuropathy Scale. Further subcategorization of diabetic peripheral neuropathy based on presence of neuropathic pain was performed with Douleur Neuropathique 4 Questionnaires. Participants with diabetes had decreased olfactory sensitivity, impaired olfactory discrimination abilities, and reduced odor identification skills when compared with controls. However, loss of olfaction ability was, at least partially, attributed to presence of neuropathic pain on subcategory assessment, although pain severity was not associated with dysfunction. Those participants with diabetes without diabetic peripheral neuropathy and those with diabetic peripheral neuropathy without neuropathic pain had similar olfactory function as controls in general. The presence of neuropathic pain, associated with limited attention and concentration, may explain at least a portion of the olfactory dysfunction witnessed in the diabetic patient population.
Introduction
Diabetes mellitus (DM) is a systemic disorder with increasing prevalence in Western civilizations. DM leads to a range of systemic complications including diabetic peripheral neuropathy (DPN), which occurs in up to 50% of diabetic patients leading to sensory, motor, and/or autonomic dysfunction (Zochodne 2008) . In addition, DM also contributes to central nervous system neurodegenerative processes, including brain atrophy and cognitive decline (Biessels et al. 2008 ). As such, DM can be considered a cause of widespread neurodegeneration. Other neurodegenerative disorders have recently been identified to have premonitory olfactory dysfunction that may even predict later disease development, such as with Parkinson's disease (Ponsen et al. 2004; Haehner et al. 2007; Siderowf et al. 2012 ), Alzheimer's disease, multi-infarct dementia (Gray et al. 2001) , and multiple sclerosis (Lutterotti et al. 2011) . Hallmarks of neurodegenerative processes, including loss of anterior olfactory neurons and presence of neurofibrillary tangles and senile plaques, can even be identified in olfactory bulbs (ter Laak et al. 1994) . In these disorders, clear olfactory dysfunction may herald further neurodegeneration (Devanand et al. 2000; Baba et al. 2012) . As a result, widespread use of olfactory testing has been used to assist in diagnosing these neurodegenerative conditions at earlier stages or even prior to clinical phenotype development (Lojkowska et al. 2011) .
As DM contributes to neurodegeneration, an ability to predict those patients susceptible to development of neurodegeneration would potentially assist in future early preventative management. DM has been reported to have olfactory and chemosensory components previously (Jorgensen and Buch 1961; Patterson et al. 1966; Weinstock et al. 1993; Bramerson et al. 2004; Vennemann et al. 2008) ; however, interestingly, this may depend on the presence of other complicating comorbidities (Naka et al. 2010) . The nature of comorbidity contribution remains unclear; however, a prior study did not determine the presence of peripheral neuropathy, a form of neurodegeneration, to impact on olfactory dysfunction although how peripheral neuropathy was determined in that study is unclear (Weinstock et al. 1993) . Another study examining patients with peripheral neuropathy identified loss of odor identification abilities with greater severity of peripheral neuropathy, but there was no assessment on the presence of neuropathy-associated neuropathic pain (NeP) (Heckmann et al. 2009 ). Previous studies even determined that loss of gustatory function occurs in patients with DPN (Heckmann et al. 2009 ) and was predictive of later peripheral neurodegeneration in DM patients (Le Floch et al. 1992) . Therefore, it is unclear if presence of DPN may be associated with olfactory dysfunction. Although previous studies divided patients with DM to have comorbidities or not (Naka et al. 2010) , we chose to specifically examine for any association with olfactory dysfunction and the presence of DPN, a sign of peripheral neurodegeneration.
A potent complication of DM is the presence of NeP associated with development of DPN (Argoff et al. 2006; Toth and Au 2008) . Pain is associated with elevation of olfactory thresholds in the absence of DM (Siviero et al. 2010) , perhaps due to attention disruption (Oosterman et al. 2011) . When considering a population of patients with DM must consider the presence of pain as a comorbidity due to its high prevalence (Davies et al. 2006) . We hypothesized that DM participants would have impaired olfactory function when compared with control non-DM participants, but we also studied 3 groups of DM patients: 1) patients without DPN or NeP; 2) patients with DPN without NeP; and 3) patients with DPN and NeP in order to determine the potential influences of the presence of DPN and NeP on DM-mediated olfactory dysfunction, if present. In particular, we sought to determine if olfactory testing was feasible in cohorts of patients with type 2 DM with or without DPN, and whether or not olfactory dysfunction could predict the presence of peripheral neurodegeneration manifesting as DPN. If so, future studies would be planned to determine if olfactory dysfunction could herald development of DPN in patients with type 2 DM. Potential clinical outcomes in this scenario could include using olfactory screening to determine patient eligibility for clinical trials to prevent onset of DPN once type 2 DM is present.
Materials and methods

Participant recruitment
Ethical approval for this study was received from the University of Calgary Centre for Advancement of Health. Recruitment of patient participants occurred from December 2008 to July 2011 using patients recruited from posters placed within the Neuromuscular, Neuropathic Pain and Endocrinology Clinics at the University of Calgary. Control participants were age matched and culled from staff working at each of the clinics participating in this study or as family or friends of participants. All participants provided informed written consent prior to their involvement.
All participants completed a standard pretesting history questionnaire to document the presence of the following: cystic fibrosis, Addison's disease, any renal disease, any thyroid disorders, endometriosis, known zinc deficiency, dry mouth syndrome, cardiac conditions, malignancy, nasal trauma or deformity, prior head traumas, previous episodes of lost consciousness, smoking history, pregnancy, menstruation, gynecological disorders, and the presence of any psychiatric conditions or alcohol or recreational drug dependence. All prescribed and nonprescribed medications and supplements taken were recorded.
Patient participants all had a diagnosis of preexisting type 2 DM. Presence of DM was verified by 2 separate positive results: 2 prior fasting glucose results of ≥7.1 mmol/L (126 mg/ dL) or 2 oral glucose tolerance tests leading to a 2-h serum glucose of ≥11.1 mmol/L (200 mg/dL) (based on Canadian Diabetes Association guidelines). These patients then underwent further clinical and laboratory evaluation for the presence of DPN. The age of diagnosis of DM and the duration of symptoms of DPN (if present) were recorded. In addition to the history questionnaire completion, patient participants found to have DPN were also assessed for the presence of other systemic illnesses, prior or current alcohol dependence (based on Diagnostic and Statistical Manual of Mental Disorders-IV criteria), and toxin and medication exposures, and family history of neuropathy was documented to assess and exclude other potential causes of peripheral neuropathy. Intake of anti-DM agents and other medications was recorded. A general examination was performed for DM patients with DPN including cardiac, respiratory, abdominal, and dermatological assessments. There was no specific diagnostic testing of the cardiac, hepatic, or renal systems undertaken.
All patient participants found to have DPN underwent laboratory testing within 1 month of study to examine for other causes of peripheral neuropathy including a complete blood count, electrolytes, urea, creatinine, alanine aminotransferase, aspartate aminotransferase, gammaglutamyltranspeptidase, alkaline phosphatase, albumin, total bilirubin, international normalized ratio, thyroid stimulating hormone, erythrocyte sedimentation rate, antinuclear antibody, extracted nuclear antibody, serum protein electrophoresis, rheumatoid factor, lactate, serum folate, cobalamin, and fasting methylmalonic acid (Calgary Laboratory Services). Hemoglobin A1C (HbA1C) was also measured in all DM patient participants. Within 1 month of testing, control participants underwent glucose tolerance testing and HbA1C measurements and were excluded if laboratory results indicated presence of DM or impaired fasting glucose. Patients were excluded if potential causes for peripheral neuropathy other than DM was identified, if they had impaired glucose tolerance only, or if they had a juvenile onset of DM or frank requirement for insulin at diagnosis (i.e., possible type 1 DM). Lastly, participants were excluded if they refused concurrent laboratory testing.
Participant assessment and allocation
Complete standardized neurological examinations were carried out in all participants, including tone, power, deep tendon reflexes, sensory function, Romberg testing, gait, and tandem gait. Each participant was also scored using the Toronto Clinical Scoring System (TCSS) (Bril and Perkins 2002) and the Utah Early Neuropathy Scale (UENS) (Singleton et al. 2008 ) to gauge severity of DPN, performed by an unblinded investigator prior to performance of olfaction testing. After clinical scales were completed, patient participants were categorized to have either DM only (both TCSS ≤ 3 and UENS ≤ 3) or DM with DPN (both TCSS > 5 and UENS > 6). Those DM patient participants with a TCSS score of 4-5 and/or a UENS score of 4-6 were excluded due to uncertainty regarding the presence or absence of DPN. As well, control participants were excluded from participation if TCSS > 4 and/or UENS > 3. We further categorized patient participants with DPN as having NeP or not based on the question "Do you have pain on a daily or near daily basis?" If patient participants answered yes, then they were asked to complete the Douleur Neuropathique 4 Questionnaire (DN4Q), which categorizes pain as neuropathic or nonneuropathic in nature with good sensitivity (82.9%) and specificity (89.9%) (Bouhassira et al. 2005) . Patient participants scoring ≥4 on the DN4Q were categorized to have DPN with NeP (DPN-P), whereas patient participants denying any pain or discomfort (answering "no") were categorized as DPN without NeP (DPN-NoP). If patient participants admitted to having pain, but had a score of <4 on the DN4Q, then they were excluded from further participation. For patients categorized as DPN-P, their pain must have persisted for at least 3 months, and pain severity must have been estimated to be ≥40 mm on the 100-mm visual analog scale (VAS) of the Short-Form-McGill Pain Questionnaire (Melzack 1987) ; or patients were excluded due to uncertainty of how mild severities of chronic pain could influence results. For all participants, exclusion criteria for conditions that could impact on olfaction or its testing were also considered: a history of seizure/convulsions, clinically significant cardiac disease or dysfunction, postural or uncontrolled hypotension, severe hepatic impairment, renal failure requiring hemodialysis, chronic obstructive pulmonary disease, stroke, dementia or mild cognitive impairment, Parkinsonism, a history of significant head trauma, smoking, or use of a medication with a known influence on olfactory function. We recorded the medications being used for DM and ancillary conditions, as well as for DPN-P patient participants taking pain relief medications.
Olfactory sensory testing
We used standardized Sniffin' Sticks for olfactory testing (Freiherr et al. 2012 ). All participants were blindfolded during the 1-h assessment. Assessors were not informed of participant group allocation. Odor detection threshold for phenyl ethyl alcohol was assessed (Hummel et al. 1997 ) using a 3-alternative forced-choice (AFC) ascending staircase paradigm (Wetherill and Levitt 1965) . A total of 16 steps with a 1:2 dilution series starting at 4% using 1,2-propanediol (Sigma-Aldrich) as the diluent were used. The assessor presented 3 sticks in a randomized order; 2 contained the solvent and the third contained the odorant at a certain dilution, and the blindfolded participants were asked to identify the odor-containing stick. Reversal of the staircase occurred when the odor was correctly identified in 2 successive trials with a subsequent reversal of the staircase when participants failed to correctly identify the odor. A total of 7 reversals were collected, with the geometric mean of the last 4 reversals serving as a threshold estimate.
Odor quality discrimination was assessed using the Sniffin' Sticks 16-triplet AFC odor discrimination test (Hummel et al. 1997) . Participants were presented with 3 odor-containing sticks in random order, 1 at a time. Two sticks smell the same and 1 stick smells qualitatively different. Using different odor combinations for each trial, participants were asked to identify the stick that smelled different.
Cued odor identification was assessed using the Sniffin' Sticks 16-item 4-AFC cued odor identification test (Hummel et al. 1997) . For each pen, participants were asked to select which of 4 odor choices (words shown on cards) best described the odor they smelled. Participants were permitted to test 1 odor stimulus multiple times before concluding and were not permitted to return to testing prior odor stimuli presented.
Subjective odor ratings were assessed using individual 10-point VAS. Participants were presented with 4 Sniffin' Sticks from the cued odor identification test. The odorants were composed of 2 negative odors and 2 positive odors; one odor of each of the 2 valence groups was familiar, whereas the other was unfamiliar. Pleasantness and familiarity ratings were obtained from published normative data in a NorthAmerican sample (Freiherr et al. 2012) . Participants rated each odor on pleasantness, intensity, and familiarity.
Statistical analysis
Group equivalence for participant age, duration of type 2 DM, duration of DM and DPN symptoms, and HbA1C were compared by 1-way ANOVA testing; gender was compared by chi-square testing. The primary outcome measure was a joint difference in 2 scores for olfactory threshold and discrimination. To test for statistical differences in olfactory processing between the groups, we initially performed a general MANCOVA using odor detection threshold, odor quality discrimination, odor identification, and ratings of odor pleasantness and odor intensity as dependent measures and "general diagnosis" (patient participants diagnosed with DM, independent of subgroup, or control participants) as an independent measure. In the case of difference in age or durations of disease, we would include the appropriate factor as a covariate factor, with statistical differences for each dependent measure assessed using separate ANCOVAs. We then assessed for potential differences in the aforementioned comparison between performances for subgroups of DM (DM only, DPN-P, and DPN-NoP) and control participants using MANOVA testing with the same dependent measures as above but using the variable "specific diagnosis" as an independent variable. Statistical differences for each dependent measure were subsequently assessed using separate ANCOVAs and followed up with pairwise Bonferroni post hoc tests. Finally, we performed post hoc linear regression analyses to determine relationships between olfactory testing performances (independent variables) and age, duration of diabetes, severity of diabetes (using HbA1C measurements), severity of peripheral neuropathy, and pain severity (dependent variables) using pairwise Bonferroni corrections for multiple comparisons. For gender comparisons, we performed post hoc ANCOVA testing.
Results
Patient and control participants
A total of 74 potential participants were screened for study involvement. Of these, 19 were labeled as healthy control participants (11 women), 19 were patients diagnosed with noncomplicated DM (DM only) (7 women), 15 were patients diagnosed with DM with DPN-NoP (7 women), and 21 were patients diagnosed with DM with DPN-P (12 women). Of these, 4 participants were excluded from all analyses; 3 participants were excluded from the DPN-P group: one had been previously hospitalized due to exposure to chemical fumes, one showed amotivation for testing indicated by very low scores in all measures and experimenter observation, and another participant failed to have perceptual ratings performed. One other participant from the DPN-NoP group was excluded due to presence of sinus infections at the time of potential enrollment. Therefore, we analyzed data from a total of 70 participants (Table 1) . Of the assessed participants with DPN, no other causation for peripheral neuropathy was present.
As there was a significant difference between the subgroups (DM only vs. DPN-NoP and DM only vs. DPN-P) with respect to age, a variable with known influence on odor processing (Larsson et al. 2000) in diabetes studies (Doty et al. 1984) , we included age as a covariate to factor out variance attributable to age differences.
For the general diagnosis of DM, we assessed for any general reduction in olfactory function with comparison to the control participant group. DM patients demonstrated a general significant reduction in olfactory function when compared with the control group (F(6, 63) = 2.68, P = 0.02). Subsequent testing using age as a covariate demonstrated that the DM patient participants had reduced odor detection thresholds (F(2, 67) = 3.90, P = 0.03), reduced ability to discriminate between odor qualities (F(2, 67) = 6.83, P < 0.01), reduced ability to identify the odor (F(2, 67) = 4.48, P = 0.02), and rated odors as less intense (F(2, 67) = 11.87, P < 0.01) than did the control participant group (Table 2) . However, there was no significant difference between the DM and control participant groups with how they rated pleasantness of the odors (F(2, 67) = 0.15, P > 0.86).
Next, we assessed whether the aforementioned effects were mediated by a DM subgroup, once again using age as a covariate. There was a significant effect of patient participant classification when all olfactory functions were assessed together (F(6, 18) = 2.03, P = 0.01). Separate analyses demonstrated significant group differences for odor detection threshold (F(4, 65) = 3.09, P = 0.02; Figure 1 ). Pairwise comparisons using Bonferroni post hoc tests demonstrated that this difference was mediated primarily by the DPN-P group that had significant lower detection threshold than the control participant group (P < 0.01), as well as the DM-only subgroup (P < 0.01), but not the DPN-NoP (P > 0.21; Figure 1 ). Moreover, there was a significant group effect for odor discrimination performance (F(4, 65) = 3.39, P = 0.01; Figure 1 ). The relationship was, however, more complex than for the differences in detection threshold. There was no significant difference in odor discrimination performance for the DPN-P group as compared with the control participant group (P = 0.05). However, although there was clear nominal differences, no other statistical comparison demonstrated either a statistical tendency or significant difference in quality odor discrimination performance (all P > 0.10).
There was a significant subgroup effect for the variable odor intensity. There was, however, no significant difference demonstrated between any of the 4 groups' individual values (all P > 0.10) when familiar and unfamiliar odors were grouped together. However, when the intensity ratings for familiar and unfamiliar odors were considered separately, there were discernible group differences for the familiar and nameable odors. Both groups diagnosed with peripheral neuropathy (DPN-NoP and DPN-P) rated the familiar odors to be less intense than the control participant group (P < 0.049 and P < 0.01, respectively), whereas there was no significant difference between the DM-only and control participant group (Figure 1 ). There was no significant difference between subgroups for intensity ratings of unknown Values shown are mean ± SD. *P < 0.05 (1-way ANOVA testing) for comparison of subject groups with respect to age and duration of DM. 2) than the odors designated as unfamiliar (mean rating = 6.49, SD = 2.0). Finally, there was no significant difference between subgroups in their ability to identify suprathreshold odors (F(4, 65) = 2.35, P = 0.06) or in how they rated odor pleasantness (F(4, 65) = 2.34, P = 0.06). Post hoc analyses of relationships between potentially important variables and olfactory testing outcomes were Odor quality discrimination 12.7 ± 2.6 10.8 ± 2.8** 11.5 ± 3.1 10.6 ± 2.6 10.2 ± 2.5
Cued odor identification 12.2 ± 1.4 12.0 ± 2.5** 12.5 ± 2.5 11.3 ± 2.4 12.0 ± 2.5
Rated odor pleasantness 4.6 ± 1.2 4.7 ± 0.9 5.2 ± 0.6 4.4 ± 1.1 4.5 ± 0.8
Rated odor intensity 7.1 ± 1.6 6.0 ± 1.7** 6.5 ± 1.4 5.5 ± 2.0 5.8 ± 1.7* Values shown are means ± SDs. **P < 0.05 (MANCOVA testing) for comparison of the entire DM cohort and control subject cohort with correction for differences in age. *P < 0.05 (MANOVA testing) for comparison of the DPN-P cohort and control subject cohort. δ P < 0.05 (MANOVA testing) for comparison of the DPN-P cohort and DM-only cohort.
Figure 1
Mean performance for each clinical group and the control group for the different olfactory tasks. Odor detection (A) was compromised in the DPN-P cohort as compared with control participants and DM-only participant subgroups. When considered together, DM was associated with lower odor detection thresholds and poor odor discrimination (B). However, DM subgroups did not differ with respect to odor discrimination. There was no difference in odor identification (C) between DM and control participant groups or between subgroups. Finally, odor intensity for familiar odors (D) was poor for DM patients considered as a group and significantly impaired in DPN-P and DPN-NoP subgroups as compared with the control participant group. * indicates significant differences between the DPN-P and control participant subgroups (ANOVA, P ≤ 0.01). δ indicates a significant difference between the DPN-P and DM-only participant subgroups (ANOVA, P < 0.01). θ indicates a significant difference between the DPN-NoP and control participant subgroups (ANOVA, P ≤ 0.05). Error bars denote standard error of the mean.
performed for all patient participants with DM. There was no influence of gender (F(2, 51) = 0.56-1.02, P > 0.26) on olfactory testing results. Multiple linear regression analyses identified associations between age and olfactory discrimination (F = 7.9, R = 0.38, P < 0.003) and identification performances (F = 9.8, R = 0.40, P < 0.003), but not for odor detection thresholds. There was no association between DPN severity (UENS), duration of DM, or severity of DM (HbA1C) and olfactory testing results (F = 0.5-1.7, R = 0.08-0.17, P > 0.21). Finally, there was no association between pain severity (VAS) and any of the olfactory testing results (F = 0.4-4.6, R = 0.08-0.29, P > 0.03).
Discussion
As with prior studies that had demonstrated loss of olfactory abilities in the presence of DM, we also found that DM participants were subject to loss of general olfaction, reduced odor detection thresholds, reduced discrimination between odor qualities, reduced odor identification, and increased thresholds for odor intensity. However, our subgroup analysis determined the possibility of a contributory role played by the presence of NeP. Subgroup analysis determined differences between DM-only and DPN-P subgroups for odor detection threshold primarily due to significantly lower thresholds for odor detection in the DPN-P patient participant subgroup, but there were other tendencies for poorer performances in the DPN-P subgroup. Also, both groups with DPN (DPN-NoP and DPN-P) had heightened thresholds for familiar odor intensity detection. However, and surprisingly, there was no association of severity of DPN or pain severity with any of the olfactory testing performances. Therefore, although DM patient participants do indeed have olfactory dysfunction as identified previously (Weinstock et al. 1993) , and with uncertain association to peripheral neuropathy (Heckmann et al. 2009 ), it appears as though at least some of this effect may be mediated by inclusion of participants with NeP related to DPN, although the severity of NeP does not seem to portend this role. In particular, patients with uncomplicated DM (DM only) had no significant differences in olfactory performance when compared with control participants. Furthermore, severity of peripheral neuropathy, a marker of peripheral neurodegeneration, was not associated with olfactory dysfunction. The present findings should not be seen to discourage against further investigations of olfaction in DM patient populations and do not indicate that olfactory dysfunction is not predictive of later neurodegeneration. However, the DPN-NoP patient subgroup did not demonstrate consistent significant worsening in olfactory dysfunction despite longer duration of DM and the presence of peripheral neurodegeneration. We did not test glycemic levels at time of testing due to lack of relationship with olfactory testing in prior studies (Le Floch et al. 1992 . Prior studies have demonstrated impairments in both olfactory and gustatory testing for DM patients (Le Floch et al. 1992 Perros et al. 1996; Naka et al. 2010) , even noted half a century ago (Jorgensen and Buch 1961; Schelling et al. 1965; Patterson et al. 1966) . Interestingly, the presence of other comorbid conditions was critical for ability to identify odors (Naka et al. 2010) , whereas uncomplicated DM with absence of other comorbid conditions did not differ from the control state in olfactory and gustatory function. As a result, it remains uncertain as to whether reductions in olfactory function are due to DM's pathophysiology or complications of DM such as with DPN and NeP, drug intake, duration and severity of disease, or perhaps a combination of several factors.
Previous studies of DM and olfaction did not specifically divide patient participant groups into subgroups depending on the presence of DPN or NeP. However, the presence of smell recognition abnormalities and taste impairment has been associated with the presence of concurrent peripheral neuropathy (Le Floch et al. 1990 , 1992 . Previous studies have examined olfactory and gustatory function in patients with chronic pain conditions other than DPN. Patients with burning mouth syndrome, idiopathic trigeminal neuralgia, and trigeminal postherpetic neuralgia were studied for gustatory thresholds and olfactory thresholds with comparison to control participants (Siviero et al. 2010) . Patient participants with these oral or facial forms of chronic pain had altered gustatory thresholds and higher olfactory thresholds when compared with control participants. Interestingly, chronic pain patient participants also were subject to altered sensory thresholds for other sensory modalities as well. Although we cannot rule out the possibility of pain itself somehow altering olfactory function and processing, it is postulated that central neuroplasticity, along with limitations in attention and concentration, occurring in the presence of chronic pain may contribute to dysfunction of special senses such as with olfaction (Oosterman et al. 2011; Seifert and Maihofner 2011) .
Only particular olfactory testing paradigms detected differences between cohorts in our work. Odor discrimination and identification, both used to examine olfactory suprathreshold functioning, did not identify significant differences between cohorts. It may be that such suprathreshold paradigms are insensitive to changes in olfactory abilities, particularly as related to age and cognition (Rovee et al. 1975; Green et al. 1989; Doty et al. 1994 ). However, these are felt to be useful supplements for a comprehensive chemosensory test battery used in clinical settings (Doty et al. 1994) . Changes in odor threshold testing, more so than odor identification, seem to be related to the peripheral olfactory input (Jones-Gotman and Zatorre 1988; Hornung et al. 1998) . As well, suprathreshold testing such as with odor identification can have lower test-retest reliability (Hummel et al. 1997) . Therefore, it is not clear if the absence of suprathreshold distinctions between cohorts is related to insensitivity or lack of reliability of testing, or whether these paradoxical olfactory testing results relate to the pathological processes involved in diabetes, neuropathy, and chronic pain.
Our findings are presented with limitations to be considered. Although we identified patients prospectively, the volunteers that presented were not randomly selected from a population with type 2 DM with or without DPN and with or without accompanying NeP. We limited our studies to olfaction and did not perform gustatory testing, which may be useful in future studies. Our sample size was not based on a predetermined power analysis. We excluded patients with type 1 DM due to potential differences in neurodegeneration and to maintain a more homogeneic patient population. In published studies including subgroups of type 1 and type 2 DM patients, it has been suggested that olfactory dysfunction is greater in type 2 DM patients (Naka et al. 2010) , and perhaps also in those type 2 DM patients requiring insulin treatment (Le Floch et al. 1993 ), but when corrections for diabetic complication morbidity and age were considered, this difference may not be noticeable as reported elsewhere (Weinstock et al. 1993 ). Differences in age, which affect olfaction (Larsson et al. 2000) , were corrected as a covariate, but there were differences in duration of DM that may or may not (Naka et al. 2010 ) have also impacted on our results. Gender matching between cohorts was not complete. Also, we did not assess for socioeconomic status or personality disorders. We reported any past history of major depression or other psychiatric conditions, but did not perform formal testing for these conditions. Overall, the use of psychotropic medications and presence of major depression or an anxiety disorder was similar between cohorts, but these factors could also impact on olfactory testing performance. The use of pharmacotherapies for chronic pain was largely limited to patients with DPN-P, which could have affected performances. Although DM patients with DPN had their histories recorded to detect excessive current alcohol intake, presence of hereditary peripheral neuropathy, and general examinations performed, we did not perform these assessments in control participants or DM-only participants. Also, we did not quantify alcohol intake or glycemic levels at time of testing and therefore cannot identify associations with olfactory testing performances. The presence of pain relief medications for NeP management may have impacted on attention and concentration of DPN-P patient participants, impacting olfactory testing results. No specific psychometric testing for attention and concentration was performed with our population. Finally, the individual cohort sizes are small after categorization, and we cannot rule out the possibility of type II errors contributing to the lack of statistical associations determined-future larger studies may be more forthright.
Our results suggest that the presence of NeP in patient participants with DM related to the presence of DPN may possibly modulate the results of or modify participant performance during olfactory testing. Further studies need to examine the roles of severe refractory pain in patients with DPN as compared with DPN patients with well-treated NeP, the potential role of mild cognitive impairment in DM patients, as well as chronic pain unassociated with DM. Although our hypothesis of DM mediating olfactory dysfunction was met, it is possible that our results may indicate the importance of concurrent pain on olfactory testing results and that numerous comorbidities related to DM must be considered when olfactory function is examined in this population. However, the presence of NeP certainly does not appear to mediate all of the olfactory performance findings, as differences could not be discerned between DPN-NoP and DPN-P cohorts, and the severity of pain was also not associated with olfactory performance. Likewise, severity of DPN was also not associated with abnormal olfactory testing performances except for a group effect for familiar odor intensity scoring. Although greater deficits in odor detection threshold were found in the DPN-P cohort, there were no consistent changes for other olfactory testing measures between cohorts with DM. Therefore, further studies will certainly be required to assess the roles of DPN and the presence of NeP as factors influencing olfactory performance. We suggest that the recognition of the potential role of chronic pain as a confounding factor should be considered for all future studies examining the role of olfactory dysfunction as a potential biomarker for neurodegenerative conditions. As well, we suggest that pain's potential influence on attention and concentration should be quantified using psychometric testing to determine its potential influence on olfactory testing performances.
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